Nutriband

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It delivers abuse deterrent fentanyl transdermal system which provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. It operates through the Pocono Coated Products and Active Intelligence segments. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2012 and is headquartered in Orlando, FL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It operates through the Pocono Pharmaceuticals and 4P Therapeutics segments. The Pocono Pharmaceuticals segment relates to a coated products manufacturing entity. The 4P Therapeutics segment performs contract research and development services. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2012 and is headquartered in Orlando, FL.

ORLANDO, FL / ACCESSWIRE / April 27, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the fiscal year ended January 31, 2023. Key Highlights: Generated record revenue of $2.1 million, up 46% over the prior fiscal year Successfully obtained court verdict for recovery of shares constituting 15% of its total outstanding shares Announced a Seven-for-Six Forward stock split to reward shareholders following the successful court verdict Received notice of allowance from the Canadian Intellectual Property Office for AVERSA™ patent completing patent issuance in all of North America Demonstrated with Kindeva Drug Delivery enhanced abuse-deterrent characteristics for AVERSA™ Fentanyl Announced plans to officially launch AI tape brand in Q1 of 2023 Company COO, Alan Smith Ph.D selected for FDA Centre for Research on Complex Generics Expert Committee With Kindeva Drug Delivery, selected AVERSA™ Fentanyl Abuse Deterrent Formulation for commercial scale manufacturing process development "Our 2022 results and milestones have shown that we remain laser focused on hitting the targets we set ourselves as a company each year.

Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023

ORLANDO, FL / ACCESSWIRE / April 19, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the development of innovative transdermal solutions, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 08:30 AM (Local Time -PST). Company CEO, Gareth Sheridan will be hosting the presentation and answering questions at the conclusion.

Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023

ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into a three-year $2,000,000 Credit Line facility to provide financing through the FDA approval process into commercial scale manufacturing for the Company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology.

Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology

ORLANDO, FL / ACCESSWIRE / March 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that it has joined Webull's Corporate Communications Service Platform, which will provide Nutriband with a comprehensive suite of investor relations and corporate communications solutions. This will enable Nutriband to enhance its corporate communications efforts, expand its investor outreach, and increase its visibility among potential investors.

Nutriband Inc Joins Webull Corporate Communications Service Platform

ORLANDO, FL / ACCESSWIRE / March 2, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that Alan Smith, Ph.D., Chief Operating Officer (COO), Nutriband, and President of its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has been selected for the FDA's Center for Research on Complex Generics Stakeholder Expert Committee on Adhesion Testing for Transdermal/Topical Delivery Systems.

Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee

ORLANDO, FL / ACCESSWIRE / February 15, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its has completed the requirements to file its application with Ecuador's Health Register (Registro Sanitar Ecuador) to permit the distribution of certain medical devices and cosmetic products in South America. Ecuador is part of the Andean Community CAN.

Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health Register

ORLANDO, FL / ACCESSWIRE / January 24, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company's participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom. Gareth Sheridan, Nutriband's CEO, will give a presentation at 11:00 a.m.

Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference

Nutriband among the first issuers to dual list on Upstream ORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!

Nutriband Inc. Commences Trading on Upstream Under NTRB

Trading scheduled to Commence on Upstream January 5, 2023 ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval. "We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.

Nutriband Inc. Will Be the First Company to Dual List on Upstream

ORLANDO, FL / ACCESSWIRE / December 29, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it has begun production of its AI Tape brand with an expected launch of the product line in Q1 2023. AI Tape is designed to share many of the benefits of traditional Kinesiology Tape.

Nutriband Inc. to Officially Launch AI Tape brand in Q1 2023

Trading to Commence on Upstream January 5, 2023 under Upstream Ticker Symbol NTRB; all Upstream Participants Eligible to Receive Commemorative NFT ORLANDO, FL / ACCESSWIRE / December 14, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Trading begins on Upstream January 5, 2023 at 10:00am ET under the ticker symbol ‘NTRB.

Nutriband Approved for Dual Listing on Upstream

ORLANDO, FL / ACCESSWIRE / December 14, 2022 / RedChip Companies will air a new interview with Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) on The RedChip Money Report® on Bloomberg TV this Saturday, December 17, at 7 p.m. Eastern Time (ET).

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / December 5, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended October 31, 2022. Key Highlights: Generated record quarterly revenue of $620,000, up 118% over Q3 2021 Revenue for nine-months ended October 31, 2022, was $1,552,074, up 67% year-over-year Continued to expand AVERSA™ intellectual property portfolio with patents now issued in 44 countries; AVERSA™ patent coverage includes the U.S., Canada, Europe, Japan, Korea, Mexico, Australia, and Russia, with patents pending in China Demonstrated with Kindeva Drug Delivery enhanced abuse-deterrent characteristics for Aversa Fentanyl Applied for Dual Listing on Upstream Stockholders' equity of $9.7 million as of October 31, 2022 "Once again, we have had a record quarter for our revenue generating subsidiaries.

Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3

ORLANDO, FL / ACCESSWIRE / December 2, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announces that Gareth Sheridan, CEO, will be presenting at the RHK Capital Disruptive Growth Conference in New York City on Monday, December 5 at 10:20 AM. Mr. Sheridan will present a corporate overview with a specific focus on the Company's AVERSA technology and market opportunity.

Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

ORLANDO, FL / ACCESSWIRE / December 1, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that the Canadian Intellectual Property Office (CIPO) has granted Canadian patent No. 2,937,649, entitled "Abuse and Misuse Deterrent Transdermal Systems," with an issue date of November 1, 2022.

Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent

ORLANDO, FL / ACCESSWIRE / October 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has signed an exclusive manufacturing agreement with Fleur Marché for its CBD and Botanical Patch lines. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence will act as exclusive manufacturer for the lines of products.

Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement

Sorrento Therapeutics Inc

ORLANDO, FL / ACCESSWIRE / October 26, 2022 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ:SRNE) with results to be presented at the American College of Rheumatology (ACR) Convergence 2022 Conference on November 13, 2022 as a poster abstract entitled "Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections." "We are excited about these proof of concept clinical results and the development of Sorrento's Sofusa lymphatic delivery platform for treatment of autoimmune diseases such as rheumatoid arthritis to provide hope for those patients who do not respond adequately to conventional biologic injections," said Alan Smith, Ph.D.

Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Confere

ORLANDO, FL / ACCESSWIRE / October 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") today announced that it has accepted an invitation as a guest speaker for the 2023 Transdermal and Microneedle Conference to be held in London on January 23 and 24. The Company's presentation will be on ‘Improving existing transdermal technologies to reduce the liability profile of abusable medications' which will discuss our AVERSA technology as a reference point.

Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24

ORLANDO, FL / ACCESSWIRE / October 3, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") today announced that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). The planned dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in NASDAQ-listed Nutriband.

Nutriband Inc. Announces Application for Dual Listing on Upstream

ORLANDO, FL / ACCESSWIRE / September 8, 2022 / Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, today announced financial and operational results for the second quarter ended July 31, 2022. Key Highlights: Generated record quarterly revenue of $0.5 million, up 113% over Q2 2021 Revenue for six-months ended July 31, 2022 up 44% year-over-year Received favorable final court judgment, related to a previously rescinded acquisition in 2017; the ruling enabled the Company to cancel the 1.2 million shares ( 1.4M shares when adjusted for 7 for 6 forward split), representing 15% of Nutriband's outstanding shares at the time, held by the defendants.

Nutriband Inc. Reports Revenue Up 113% YoY in Q2

ORLANDO, FL / ACCESSWIRE / August 16, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that the 7:6 forward split of its common stock was effective at the opening of trading on Friday, August 12, 2022, with a record date of Monday, August 15, 2022. At the effective time of the stock split, every six (6) shares of NTRB common stock were converted into seven (7) shares of common stock, without any change in the par value per share.

Nutriband Inc. Provides Update on Seven-for-Six Forward Stock Split

ORLANDO, FL / ACCESSWIRE / August 10, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced on July 27, 2022 that its Board of Directors had approved and declared a 7:6 forward split of its common stock with a record date of Monday, August 15, 2022 (the "Stock Split"). Each shareholder of record as of the record date will receive one (1) additional share of common stock for each six (6) shares held as of the record date.

Nutriband Inc. Details of Seven-for-Six Forward Stock Split

ORLANDO, FL / ACCESSWIRE / August 1, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for its patent application, CA 2937649, entitled "Abuse and Misuse Deterrent Transdermal Systems," that protects its AVERSA™ transdermal abuse deterrent technology. The issuance of this Canadian patent in combination with patents already issued in the United States and Mexico provides intellectual property protection for Nutriband's Aversa™ products across North America.

Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent

ORLANDO, FL / ACCESSWIRE / July 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 7:6 forward split of its common stock that is expected to be effective at 12:01AM on August 15 and in effect at the opening of trading on Monday August 15, 2022. At the effective time of the forward stock split, every six (6) shares of NTRB common stock will be converted into seven (7) shares of common stock, without any change in the par value per share.

Nutriband Inc. Announces Seven-for-Six Forward Stock Split

ORLANDO, FL / ACCESSWIRE / July 26, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it has received the Final Judgment in favor of the company, effectively allowing the company to cancel 1.2M shares held by the defendants in the Court case filed in Orlando, Florida, by the Company. The shares in question equate to approximately 15% of the Company's shares now outstanding.

News for Nutriband Stock (NTRB)